Healthcare innovation is failing because there is an abundance of breakthroughs and a lack of structure to support them.
Validated intellectual property is consistently pushed into traditional startup models: capital-heavy, timeline-extended, and misaligned with how strategic acquirers actually evaluate risk. Promising technologies are stalling indefinitely between proof-of-concept and acquisition readiness.
We built Promptus to close the gap.
A venture studio with a laser focus on advancing healthcare technologies through a disciplined model designed for efficiency, regulatory alignment, and strategic exit. We don’t build startups, we build technologies.
Building Technologies the Right Way
OUR POINT OF VIEW
Universities and hospitals generate thousands of healthcare innovations each year.
What’s missing is a repeatable system that:
-
Identifies commercially viable IP early
-
Aligns development with regulatory pathways from day one
-
Deploys capital in milestone-based stages
-
Positions technologies with strategic buyers long before exit
We believe healthcare innovation should be:
-
Capital disciplined
-
Regulatory aware from inception
-
Exit-oriented by design
-
Built by operators, not just founders
That philosophy guides everything we do.
For Investors
Promptus offers a structured model for advancing healthcare technologies with:
-
Defined development milestones
-
Dedicated SPVs for capital efficiency
-
Early buyer positioning
-
Clear regulatory pathways
Our approach is designed to reduce timeline drift and improve capital deployment compared to traditional startup models.
WHO WE WORK WITH
For Inventors
& Clinicians
If you have validated IP but lack the infrastructure to commercialize it, Promptus provides:
-
Structured IP acquisition and protection
-
Engineering and regulatory execution
-
Milestone-based development planning
-
Strategic positioning toward exit
We focus on turning promising innovation into executable development programs.
For Tech Transfer Offices
Promptus partners with institutions to:
-
Evaluate IP for patent defensibility and regulatory fit
-
Identify assets aligned with real market demand
-
Structure acquisition and development pathways
-
Advance technologies beyond early-stage stagnation
Our goal is to help high-potential IP move forward without stalling.
06 | Exit
Strategic buyer mapping begins early. Technologies are positioned for acquisition or licensing once validated and de-risked.
05 | Certify
Regulatory strategy, including 510(k) planning, is integrated into development from day one.
04 | Build
Experienced specialists lead engineering, prototyping, verification, and validation.
02 | Acquire
We secure and protect intellectual property through structured patent strategy and ownership alignment.
01 | Discover
AI-assisted evaluation identifies IP with strong patents, Class II regulatory alignment, and clear commercial pathways.
03 | Finance
We secure and protect intellectual property through structured patent strategy and ownership alignment.
The Expedited Innovation Platform (EIP)
OUR APPROACH
Our proprietary framework advances validated IP from discovery to acquisition-ready asset within 18–30 months. The EIP considers regulatory, engineering, capital, and commercial positioning from the beginning. In other words, we begin with the end in mind.
OUR LEADERSHIP TEAM
Gary Graham
Executive Chairman
Chris Franks
President & CEO
Patrick McCain
Chief Operating Officer
Benjamin Sanchez-Terrone
Chief Scientific Officer
OUR ADVISORS
Dr. M. Kim Saxton
University at Buffalo
Dr. Todd Saxton
University at Buffalo
OUR MISSION
We are committed to bringing 100 meaningful health innovations to market over the next decade.
By combining financial discipline, operational rigor, and regulatory expertise, we aim to accelerate technologies that expand understanding of human physiology and support the future of healthcare.